Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, Brazil.
Departamento de Neurologia/Neurociência, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
Mol Psychiatry. 2018 Jan;23(1):94-106. doi: 10.1038/mp.2017.188. Epub 2017 Sep 26.
Psychiatric disorders are debilitating diseases, affecting >80 million people worldwide. There are no causal cures for psychiatric disorders and available therapies only treat the symptoms. The etiology of psychiatric disorders is unknown, although it has been speculated to be a combination of environmental, stress and genetic factors. One of the neurotransmitter systems implicated in the biology of psychiatric disorders is the purinergic system. In this review, we performed a comprehensive search of the literature about the role and function of the purinergic system in the development and predisposition to psychiatric disorders, with a focus on depression, schizophrenia, bipolar disorder, autism, anxiety and attention deficit/hyperactivity disorder. We also describe how therapeutics used for psychiatric disorders act on the purinergic system.
精神障碍是使人虚弱的疾病，影响全球超过 8000 万人。目前还没有针对精神障碍的病因治疗方法，现有的治疗方法只能治疗症状。精神障碍的病因尚不清楚，尽管有人推测它是环境、压力和遗传因素的综合作用。在精神障碍的生物学中，涉及的神经递质系统之一是嘌呤能系统。在这篇综述中，我们对嘌呤能系统在精神障碍的发展和易感性中的作用和功能进行了全面的文献检索，重点是抑郁症、精神分裂症、双相情感障碍、自闭症、焦虑症和注意缺陷/多动障碍。我们还描述了用于治疗精神障碍的疗法如何作用于嘌呤能系统。
